EFI Global’s Post

Injectable Drug Delivery Market: Precision, Convenience, and Care! 💉💊 Market Scope: The injectable drug delivery market is estimated to increase at a CAGR of 11.26% over the forecast period. The global injectable drug delivery market is anticipated to reach $1466.26 billion by 2029. Sample Report Link: https://cutt.ly/Jw35f6Vb Injectable Drug delivery Market Overview The recent growth in the prevalence of cancer and diabetes, where injectable medications are used in therapy, as well as the current trend of producing safety syringes, prefilled syringes, and auto-injectors, are driving the market. The accessibility of alternatives to drug delivery processes, as well as safety concerns caused by an increase in needle sticks during treatment, are major barriers to the global injectable drug delivery industry. #injectable #drug #delivery #market #wrinkles #music #food #bitcoin #injectables #rap #togo #business #medspa #newyork #usa #marketing #xeomin #fitness Key Players : 1. Baxter International Inc. 2. BD 3. Gerresheimer Küssnacht AG 4. Pfizer, Inc., 5. SCHOTT Pharma AG,

In bid to reassure investors, Lilly says it will build manufacturing capacity at risk for next-gen obesity drug >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #productmarketing #healthcare

A type 2 diabetes medication caught social media frenzy to become a weight loss magic drug. Semaglutide or commonly know as Ozempic made its manufacturer, Novo Nordisk, the most valuable company in Europe in 2023. Enter Zepbound, a new weight loss drug from Eli Lilly and Company at a lesser cost & less obvious side effects, and the weight loss space heats up to unprecedented levels. The frenzy is similar to the acceptance of Viagra, a drug meant to treat heart conditions but glorified for other reasons 😂 Bloomberg Intelligence report estimates the weight loss industry to boom from USD 2.5 Billion (2022) to an estimated USD 80 Billion by 2030. Interesting to see how this space gears up, how more pharma companies join the band wagon and how these drugs are regulated for general usage. Obesity is no longer a state of health, it’s a commodity and might just be the biggest commodity in near future 🫄🏼🫃🏼 #ozempic #novonordisk #zepbound #elililly #bloomberg #bloombergintelligence #pharma #pharmaceutical #socialmedia #newtrend #interesting #2024trends #obesity #lifestyle #nextbigthing

Obesity: it’s a hot topic with rates in the U.S. rising to 41.9% in 2020. This epidemic has opened a door for pharmaceutical manufacturers, and weight loss drugs have taken off in recent years.  Check out Definitive Healthcare’s latest blog on how #GLP1 drugs are reshaping the health of Americans and the impact it could have on the economy: https://lnkd.in/e-abBKy4  

We are thrilled to unveil our highly anticipated 2024 Global Pharmaceuticals Reputation Report! 💊 The past year has been a landmark period for the #pharmaceutical industry, driven by blockbuster weight-loss drugs like #Wegovy and #Zepbound that promise to transform lives and redefine health and wellness standards.   These medicinal breakthroughs have captivated the public, offering hope to millions struggling with #obesity and related health issues.   The 2024 report explores these developments in two parts.   1. Section one is a snapshot of the sector’s current reputation and shows how key metrics have changed since our previous analysis in February 2023.    2. Section two shifts gear and reveals the results of our exclusive survey of stakeholder perceptions of weight-loss drugs. We reveal what the public thinks about the causes of obesity, the biggest issues associated with the drugs, and which pharma companies are most associated with them.   Taken together, the rankings and survey responses will raise eyebrows and provide valuable insights for pharma companies looking to improve their reputation and increase trust among #stakeholders.   We hope you enjoy reading the report. Find a short sneak peek below. For full report follow the URL in the 1st comment.

#Biosimilars are highly similar #biological products to existing, FDA-approved drugs. They offer a more affordable option for patients while maintaining comparable safety and efficacy. This is particularly beneficial for treating chronic and autoimmune conditions, a rapidly growing healthcare concern. According to the Insights10 market research report, the global biosimilar market is mirroring this growth, with a projected value of a staggering $97.4Bn by 2030. This significant increase represents a CAGR of 18.32%, building upon a robust $30Bn market in 2023. This surge is driven by several factors, including the rising prevalence of chronic diseases and the cost-effectiveness of biosimilars. Further accelerating market momentum, the FDA has played a crucial role by approving a total of 49 biosimilars. Notably, 4 of these approvals came just this year in 2024, signifying a commitment to expanding treatment options and increasing affordability for patients. #fdaapproval #biosimilarmarket #drugs

Obesity: it’s a hot topic with rates in the U.S. rising to 41.9% in 2020. This epidemic has opened a door for pharmaceutical manufacturers, and weight loss drugs have taken off in recent years.  Check out Definitive Healthcare’s latest blog on how #GLP1 drugs are reshaping the health of Americans and the impact it could have on the economy: https://lnkd.in/eQaBbhqD  

🟢🔵 𝗧𝗵𝗲 𝗿𝗶𝘀𝗲 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝘄𝗲𝗶𝗴𝗵𝘁 𝗹𝗼𝘀𝘀 𝗱𝗿𝘂𝗴𝘀, 𝗴𝗮𝗺𝗲-𝗰𝗵𝗮𝗻𝗴𝗲𝗿𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆! Ozempic and Wegovy, two of the most popular drugs in this category, are being hailed as game-changers in the treatment of diabetes and obesity. By mimicking the body's natural GLP-1 hormone, these drugs help suppress appetites, leading to weight loss and better blood sugar management. The results are astonishing - patients have lost between 15% to 26% of body weight within 18 months, depending on the drug and dosage. With analysts predicting that the anti-obesity market may become the largest pharmaceutical market in history, it's no wonder that GLP-1 drugs are becoming increasingly attractive and profitable. 👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 : 𝗚𝗔𝗠 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀 : https://lnkd.in/egjkxbQK 𝗡𝗼𝘃𝗼𝗻𝗼𝗿𝗱𝗶𝘀𝗸 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 :https://lnkd.in/eYtxfzE9 𝗝.𝗣. 𝗠𝗼𝗿𝗴𝗮𝗻 : https://lnkd.in/eGhC5ysW #GLP1 #obesity J.P. Morgan GAM Investments Image Source : Novonordisk Investor Presentation

Obesity: it’s a hot topic with rates in the U.S. rising to 41.9% in 2020. This epidemic has opened a door for pharmaceutical manufacturers, and weight loss drugs have taken off in recent years.  Check out Definitive Healthcare’s latest blog on how #GLP1 drugs are reshaping the health of Americans and the impact it could have on the economy: https://lnkd.in/dSpU62wp  

Tackling obesity with medication: New hope and real challenges. Pharmaceuticals could be manufactured and sold at reasonable profit, far below the current eye-watering prices, according to a paper in the journal. Read More: https://shorturl.at/KQW02 #Obesity #WorldObesityDay